Replimune to ride wave of physician support to launch advanced melanoma therapy
RegulatoryapprovedTudriqevPositive
AI Analysis
Summary
Replimune received FDA approval for Tudriqev for advanced melanoma treatment and plans to launch the therapy with strong physician support. Analysts project peak sales of $1.3 billion by 2035.
Financial Highlights
Guidance
Peak sales of $1.3 billion projected for 2035
Outcome Details
FDA approval of Tudriqev for advanced melanoma
Importance:8/10
Sentiment:
0.80
FDA approvalmelanomacommercializationpeak sales projection
Related Companies
Read the original article
Published by BioSpace on August 7, 2026 2:17 PM